July 20 (Reuters) – Tempus AI said on Monday it would acquire Personalis for about $1.5 billion to bringing its cancer test to the AI-enabled precision medicine firm's oncology portfolio. (Reporting
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)